News | December 19, 2025
Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The combination also outperformed chemotherapy on another important secondary endpoint
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Subscribe To Our Newsletter & Stay Updated
